Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of “Hold” by Analysts

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been assigned a consensus rating of “Hold” from the eight ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $20.40.

Several analysts recently commented on KROS shares. Wall Street Zen downgraded shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Weiss Ratings downgraded shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 15th. Finally, Wells Fargo & Company cut their price objective on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, March 5th.

Keros Therapeutics Price Performance

Shares of Keros Therapeutics stock opened at $10.69 on Friday. The company has a 50-day moving average of $11.06 and a 200 day moving average of $14.67. The firm has a market cap of $211.46 million, a price-to-earnings ratio of -3.55 and a beta of 0.94. Keros Therapeutics has a 1 year low of $9.69 and a 1 year high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.19). The business had revenue of $0.37 million during the quarter, compared to the consensus estimate of $1.93 million. Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%. On average, equities analysts anticipate that Keros Therapeutics will post -5.19 EPS for the current year.

Insider Activity at Keros Therapeutics

In related news, Director Julius Knowles sold 2,625 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.73, for a total transaction of $28,166.25. Following the sale, the director directly owned 10,958 shares of the company’s stock, valued at approximately $117,579.34. This represents a 19.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.72, for a total transaction of $28,140.00. Following the sale, the director directly owned 9,767 shares in the company, valued at $104,702.24. This trade represents a 21.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 8,425 shares of company stock valued at $89,995. 20.60% of the stock is owned by insiders.

Institutional Trading of Keros Therapeutics

Several institutional investors have recently bought and sold shares of KROS. Financial Management Professionals Inc. purchased a new stake in Keros Therapeutics during the 4th quarter valued at about $29,000. Caitong International Asset Management Co. Ltd grew its position in Keros Therapeutics by 254.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after purchasing an additional 1,166 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after acquiring an additional 1,888 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in shares of Keros Therapeutics during the 1st quarter valued at about $129,000. Finally, New York State Common Retirement Fund boosted its holdings in shares of Keros Therapeutics by 264.1% during the 2nd quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock valued at $142,000 after acquiring an additional 7,700 shares during the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.